ArticleScientific reports2025
ParkMAE: a cross-linguistic masked autoencoder framework for robust Parkinson's disease detection from speech.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We introduce ParkMAE, a robust multilingual speech foundation model and comprehensive benchmarking system for Parkinson's disease assessment. We curated multiple large-scale speech datasets comprising approximately 750 h of pretraining data and 100 h of evaluation data across four languages and diverse clinical populations. Our self-supervised masked autoencoder approach, pretrained on this multilingual corpus, demonstrates superior performance achieving 39% F1 score for cross-linguistic diagnosis, outperforming existing acoustic markers (eGeMAPS) by a significant margin and maintaining comparable performance to generic speech models (Whisper), while using 89% fewer parameters. Besides, ParkMAE shows exceptional generalizability to unseen languages without language-specific finetuning. Beyond diagnosis, we systematically evaluate medication state monitoring and disease staging tasks, revealing that despite promising literature reports, current publicly available datasets and speech-based approaches fail to reliably capture these clinical dimensions. For cognitive assessment (MoCA), our model demonstrated predictive capability (F1 = 0.56), suggesting potential for speech-based cognitive monitoring. This comprehensive evaluation establishes both the capabilities and current limitations of speech-based Parkinson's disease assessment, providing a reproducible framework for future clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.